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Abstract
Although the incidence and mortality for most cancers such as lung and colon are decreasing in several countries,
they are increasing in several developed countries because of an unhealthy western lifestyles including smoking,
physical inactivity and consumption of calorie-dense food. The incidences for lung and colon cancers in a few of
these countries have already exceeded those in the United States and other western countries. Among them, lung
cancer is the main cause of cancer death in worldwide. The cumulative survival rate at five years differs between 13
and 21 % in several countries. Although the most important risk factors are smoking for lung cancer, however, the
increased incidence of lung cancer in never smokers(LCINS) is necessary to improve knowledge concerning other
risk factors. Environmental factors and genetic susceptibility are also thought to contribute to lung cancer risk.
Patients with lung adenocarcinoma who have never smoking frequently contain mutation within tyrosine kinase
domain of the epidermal growth factor receptor(EGFR) gene. Also, K-ras mutations are more common in individuals
with a history of smoking use and are related with resistance to EFGR-tyrosine kinase inhibitors. Recently, radon(Rn),
natural and noble gas, has been recognized as second common reason of lung cancer. In this review, we aim to
know whether residential radon is associated with an increased risk for developing lung cancer and regulated by
several genetic polymorphisms.
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Background
Non-small cell lung cancer(NSCLC) is the leading cause
of cancer-related death worldwide [1, 2]. During the past
decades, survival rate of lung cancer has improved mod-
erately and remains still poor (around 10 % at 5 years)
[1–5]. Although early-stage lung cancer can be treated
with good survival, most cases are diagnosed at a late
stage when surgery as usual is no longer needed. Late-
stage lung cancers observe poor response to chemother-
apy and radiotherapy, although tyrosine kinase inhibitors
were investigated to be efficient in reducing tumor tissue
in NSCLC with epidermal growth factor receptor
(EGFR) mutations. The most important risk factors are
smoking for lung cancer, however, the increased
incidence of lung cancer in non-smokers(LCINS) is
necessary to concern other risk factors [3]. Recently,
radon(Rn), natural and noble gas, has been recognized
as second common reason of lung cancer. Still, smoking
is related to lung cancer risk factor, this review focused
on NSCLC in never smokers.
Lung cancer in never smoker
Smoking explains for more than 90 % of lung cancers in
men and 75 to 85 % lung cancers in women in the
United States and European Union. Although these pat-
terns are similar in Asian men, the proportion of Asian
women with lung cancer in smoker is much lower. The
proportion of women with lung cancer who have smok-
ing differs from region even within Asia, from 25 % in
Korea to 56 % in Hong Kong [6]. Tobacco smoking still
remains the predominant risk factor for the development
of lung cancer. However, lung cancer induces also in
individuals without a history of smoking [7–9].
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LCINS has been acknowledged as a disease entity sepa-
rated from smoking-associated lung cancer [10]. Accord-
ing to the World Health Organization, the incidence of
LCINS is almost 25 % of all cases [8, 11]. Recently, there is
noticeable variance in the ratios of LCINS ranging from
nearly 10 % in males in Western and up to approximately
40 % in females in Asia [7]. However, its ethnic/genetic
attributes and/or environmental features remain still
unknown.
LCINS occurs more often in women than in men and
the major histological subtype is adenocarcinoma [10].
During decades, the incidence of lung adenocarcinoma
has increased compared to that of squamous cell carcin-
oma in western and Asian countries [12]. Small-cell lung
cancer is rarely investigated in never-smokes, while in
NSCLC, the most common histological type in never
smokers is adenocarcinoma [7, 11, 13, 14]. Toh CK et al.
[13] shown adenocarcinomas involved 69.9 % of patients
in never smokers, 39.9 % in current and 47.3 % in
former smokers [13]. Especially in Asian countries, a sig-
nificant proportion of current patients with lung cancer
are never smoker. It shown 38.3 % of 10,279 patients
with smoking status in Japan, 32.4 % of 883 patients in
Singapore, and 34.5 % of 4622 patients in Korea were
never smokers [12].
Numerous studies have been demonstrated the roles
of candidate susceptibility in LCINS and those was in-
volved in carcinogen metabolism, DNA repair or inflam-
matory response. However, their role remains still to be
identified and further studies are needed to better under-
stand the role for genetic factors in LCINS development
and treatment [7]. Recently, it has been observed LCINS
has a dramatic response to EGFR tyrosine kinase inhibi-
tors (TKIs) [15, 16]. The distinct response pattern was
associated with the higher frequencies of EGFR mutations
in never smokers [10, 15, 16].
Several studies have shown LCINS patients have better
survival compared to ever smoker patients [17, 18]. The
biologic dissimilarity of lung cancer in never-smokers
versus ever-smokers are shown in differential response
according to specific therapies including EGFR inhibitors,
and in distribution of histology such as adenocarcinoma
in never-smokers [11]. Therefore, better understanding of
the incidence rate and etiology of LCINS is important
because of the implications for therapeutic trials and
epidemiologic studies of lung cancer [7].
Genetic susceptibility and LCINS
Despite standard platinum-based chemotherapy and
newer targeted therapies, there is an increasing need for
the appropriate use of targeted and tailored therapies to
improve efficiency and response in LCINS [17, 18]. In
an attempt to improve the outcomes of the therapy, the
role of inherited genetic factors in the development of
non-smoking related carcinogenesis is investigated
(Table 1).
Recently, genome-wide association(GWAS) studies
identified specific chromosomal locus, 15q24-15q25 and
5p15.33, as one of the regions associated with LCINS.
This 5p15.33 region consists two candidate susceptibility
genes, TERT and CLPTMIL and Hsiung study included
only lung adenocarcinoma never smoker female [19–21].
Hypoxia-inducible factor-2α (also called endothelial
periodic acid-Schiff domain protein 1, EPAS1) seems to
play an important role in some carcinogenesis, though
there is no information on the relationship between
single nucleotide polymorphism(SNP) of EPAS1 and
lung cancer development so far [22]. Iwamoto S et al.
observed EPAS1 rs4953354 may be a potentially suscep-
tible marker for development of lung adenocarcinoma,
especially in female never-smokers [22].
Kang HG et al. [23] identified three SNPs (colony-
stimulating factor 1 receptor, CSF1R; tumor protein p63,
TP63; and corepressor interacting with RBPJ 1, CIR1)
were found to be significantly associated with lung can-
cer. Among them, Kang HG et al. suggested CSF1R
rs10079250 may contribute to lung cancer susceptibility
in never-smoking females [23].
The ataxia-telangiectasia mutated (ATM) gene plays a
crucial role in the DNA double-strand breaks repair
pathway. Shen L et al. [24] suggested ATM rs189037
might be associated with the risk of lung adenocarcin-
oma in Chinese non-smoking females. Furthermore,
ATM rs189037 AA genotype might be a risk factor of
lung adenocarcinoma among female non-smokers with-
out cooking oil fume exposure [24].
Yongjun Zhang MM et al. investigated the potential
association between SNPs in transglutaminase 5 (TGM5),
phosphatidic acid phosphatase type 2B (PPAP2B) and pro-
teasome subunit, alpha type 4 (PSMA4) and NSCLC sus-
ceptibility in Chinese patients who were non-smokers
[25]. The polymorphisms of TGM5, PPAP2B and PSMA4
are not major contributors to NSCLC susceptibility,
however, this primarily be attributed to the significantly
distinct genetic background of Asian populations from
western populations [25].
Until now, several reports have been studied the role
of candidate genetic polymorphisms in LCINS (Table 1),
[26–35] however, their role remains still to be identified
and further studies are needed to better understand the
role for genetic factors in LCINS developing.
Radon as one of risk factors for LCINS
Although the most established risk factor for lung
cancer is smoking in several studies, unrelated to smok-
ing risk factors such as second hand smoking, radon
exposure, cooking oil vapors and indoor coal burning,
hormonal factors, and infectious factors have been
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identified [7]. Among them, radon (Rn) is the most
important natural source of human exposure to ioniz-
ing radiation and the second leading cause of LCINS
[36, 37]. The Environmental Protection Agency (EPA)
action level is 148 Bq/m3 and the World Health
Organization (WHO) has recently lowered the recom-
mended radon exposure to levels below 100 Bq/m3 [38].
Many case–control studies have presented the association
between airborne radon exposure and lung cancer, how-
ever, several observations have analyzed the effect of radon
exposure for different categories of smoking [38]. On the
other hand, possible biologic mechanisms by radon expos-
ure might increase the risk of LCINS leading gene muta-
tion, chromosome aberrations, generation of reactive
oxygen species, up or down-regulation of cytokines, and
production of proteins associated with cell cycle regula-
tion [36].
Radon exposure and genetic factors
Sinitsky MY et al. suggested the elevated frequency of cyto-
genetic damage in people with DNA-repair gene polymor-
phisms due to chronic exposure to radon and XpG,
ADPRT, and NBS1 gene can be used as molecular genetic
markers of increased individual radiosensitivity in long-
term residents with high concentrations of radon [39]. An-
other report suggested GSTM1 and GSTT1 genes deletion
increase the risk of lung cancer and these genes
might regulate the carcinogenic pathway by radon
radiation [40, 41]. Torres-Durán M et al. shown radon
exposure of never smokers seems to be a risk factor for
lung cancer and individuals diagnosed at a younger age
might have a higher residential radon concentration
explaining an accumulative effect on lung cancer appear-
ance (Table 2) [42, 43].
Although, several studies have been demonstrated the
role of candidate genes for developing LCINS, however,
the genetic determinants for susceptibility in LCINS with
residential radon exposure are still uncertain (Table 2),
[44–50] and further studies will require analyzing the as-
sociation between radon exposure and LCINS.
Next-generation sequencing (NGS) for analyzing
of SNP in LCINS
Next-generation sequencing (NGS) is a cost-effective
technology enabled screening several genes simultan-
eously, however, its application in a clinical context needs
an established workflow to acquire available sequencing
results. When combined with various selective capture ap-
proaches, NGS has allowed for the efficient simultaneous
genetic analysis of a large number of candidate genes. Sev-
eral studies applied a polymerase chain reaction (PCR)
based NGS in determining oncogene alternations in the
state of disease progression [51–53]. PCR based NGS is an
outstanding tool to provide a comprehensive genomic
diagnosis in patients with recurrent LCINS [53]. Recently,
Vanni I et al. [51] investigated an optimized NGS
Table 1 Genetic susceptibility and lung cancer in nerver smokers
Author/year Region No. of pts. Histologic type Genetic markers
McKay JD et al. 2008 [20] France 3259 case adenocarcinoma CLPTM1L-TERT
4159 control
Hsiung CA et al. 2010 [21] Taiwan 584 case adenocarcinoma CLPTM1L-TERT
585 control
Iwamoto S et al. 2014 [22] Japan 341 NSCLC EPAS1
Kang HG et al. 2014 [23] Korea 360 lung cancer CSF1R, TP63, CIR1
Shen L et al. 2014 [24] China 1003 adenocarcinoma ATM
Yongjun Zhang MM et al. 2013 [25] China 400 NSCLC TGM5, PPAP2B, PSMA4
Sun Z et al. 2014 [26] USA 27 adenocarcinoma EGFR, TP53, KRAS, RPS6KB2, ATXN2, DHX9,
PTPN13, SP1, SPTAN1, MYOF
Bennett WP et al. 1999 [27] USA 106 lung cancer GSTM1
Ahn MJ et al. 2012 [28] Korea 446 NSCLC APCDD1, NAPG, FAM38B
Lim WY et al. 2011 [29] Singapore 433 IL6, cyclooxygenase-2, PPAR-γ, IL1RN
Li Y et al. 2010 [30] USA 1489 lung cancer 13q31.3 GPC5
Wu X et al. 2013 [31] USA 1583 NSCLC LEMD3, TMBIM, ATXN7L2, SHE, ITIH2, NUDT5
Zhou W et al. 2003 [32] USA 1091 lung cancer XRCC1, ERCC2
Hung RJ et al. 2003 [33] France 302 case lung cancer CYP1A1, GSTM1
1631 control
Liu L et al. 2014 [34] China 298 case lung cancer GPC5
599 control
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Table 2 Genetic susceptibility in subjects with high radon concentration
Author/year Region Subjects Gene
Sinitsky MY et al. 2015 [39] Russia children ADPRT, hOGG1, NBS1, XRCC1, XpC, XpD, XpG
Ruano-Ravina A et al. 2014 [40] Spain 792 lung cancer GSTM1,GSTT1
Bonner MR et al. 2006 [41] US 270 lung cancer GSTM1
Druzhinin VG et al. 2011 [44] Russia healthy voluteers hOGG1, ADPRT, APE1, XRCC1, XpG, XpC, XpD, NBS1
Kiuru A et al. 2005 [45] Finland 84 healthy nonsmokers OGG1, XPD, XRCC1, XRCC3
Yngveson A et al. 1999 [46] Sweden 83 nonsmoking lung cancer p53
250 smoking lung cancer
Hayes VM et al. 1996 [47] South Africa SCLC TP53
Takeshima Y et al. 1996 [48] Japan 28 adenocarcinomas non smoking female p16/CDKN2, p53
Leng S et al. 2013 [49] USA 267 SCC case SIRT1
383 control
Leng S et al. 2015 [50] USA 242 SCC IL-6
336 control
Fig. 1 Strategy for detecting lung cancer-related genes using exom sequencing based on NGS in LCINS tissues
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workflow analyzing 22 lung cancer-related genes to se-
quence critical samples such as DNA from formalin-fixed
paraffin-embedded (FFPE) blocks [51]. Masago K et al.
[52] shown NGS is able to detect EGFR T790M mutations
in cases not easy to diagnose by other conventional
methods and play a role in acquired EGFR-TKIs resist-
ance, showing the need for alternative treatment strat-
egies, with PCR-based NGS playing an important role in
disease diagnosis.
Here, we suggest the strategy based on NGS enabled to
detect lung cancer-related genetic mutations in LCINS
patients with radon exposure (Fig. 1). We will optimize
exom sequencing based on NGS platform to analyze
LCINS-related gene in normal and lung cancer tissues.
Conclusion
Several etiologic factors have been proposed for the
development of LCINS, including exposure to radon,
cooking fumes, asbestos, heavy metals, and environmen-
tal tobacco smoke, human papillomavirus infection, and
inherited genetic susceptibility. However, the relative sig-
nificance of radon exposure and genetic polymorphisms
in the development of LCINS has not been well-
characterized. This review summarized whether radon ex-
posure is associated with an increased risk of developing
lung cancer and regulated by several genetic polymor-
phisms in never smokers.
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